|
|
|
| Effect of Levothyroxine Tablet on Serum sIL-2R CD44V6 TSGF Levels and p27 Expression in Elderly Patients with Thyroid Carcinoma |
| HU Kun, LI Chunyan, TONG Yanchu |
| Jingzhou Central Hospital, Hubei Jingzhou 434020, China |
|
|
|
|
Abstract Objective: To study the clinical effect of levothyroxine on the expression of p27 protein of elderly patients with thyroid cancer. Methods: 106 elderly patients with thyroid cancer in our hospital from Jun. 2014 to Jun. 2017 were divided into control group and observation group by simple random grouping method, 53 cases in each group. The control group was given hormone replacement therapy, the observation group was given levothyroxine treatment, both groups were treated for 1 month. The changes of serum sIL-2R,CD44V6, TSGF levels, T lymphocyte subsets levels and p27 expression in the thyroid cancer tissues before and after treatment were compared between two groups. Results: After treatment, the serum levels of sIL-2R, CD44V6 and TSGF in the observation group were (378.65±30.14)μ/mL,(310.84±21.78)ng/mL,(58.86±6.78)μ/mL, which were significantly lower than those of the control group [(436.90±33.72)μ/mL, (382.43±26.06)ng/mL, (62.73±7.40)μ/mL] (P<0.01). The serum levels of CD3+ and CD4+ in the observation group were (67.02±8.31) and (27.56±4.27), which were significantly higher than those of the control group [(58.94±7.83) and (35.07±3.88)] (P<0.01). The serum CD8+ level of observation group was (23.05±4.22), which was significantly lower than that of the control group (31.43±3.57) (P<0.01); the positive rate of p27(75.47%) expression in observation group was significantly higher than that of the control group (54.72%) (P=0.02). Conclusion: The levothyroxine tablet can decrease the expression of serum sIL-2RnCD44V6 TSGF and inhibit the expression of p27 protein in the serum of the elderly patients with thyroid carcinoma, and it can obviously improve the immune function of the patients, which is worth popularizing in clinic.
|
|
|
|
|
|
[1] Laily N, Mojtaba M, Ali H, et al. Depressive symptoms in patients with subclinical hypothyroidism-the effect of treatment with levothyroxine: a double-blind randomized clinical trial[J]. Endocrine Research, 2015, 40(3):121~126.
[2] Vera L, Gay S, Campomenosi C, et al. Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy[J].Endokrynologia Polska, 2016, 67(4):637~644.
[3] 付守智,钟朝辉,杨燊,等.枫香脂联合左旋甲状腺素片对分化型甲状腺癌患者术后促甲状腺素抑制治疗的疗效观察[J].中华普通外科杂志,2014,29(10):787~790.
[4] 胡晓东,黄泽平.左旋甲状腺素治疗不同促甲状腺激素浓度老年亚临床甲状腺功能减退患者临床观察[J].临床军医杂志,2017,13(5):525~527.
[5] Brancato D, Scorsone A, Saura G, et al. Comparison of TSH levels with liquid formulation versus tablet formulations of levothyroxine in the treatment of adult hypothyroidism[J]. Endocrine Practice, 2014, 20(7):1~17.
[6] 乔侨,石礼红,包姿萍.左旋甲状腺素对妊娠合并甲状腺功能减退患者妊娠结局的影响[J].安徽医药,2017,21(9):1709~1711.
[7] Bagattini B, Cosmo C D, Montanelli L, et al. The different requirement of L-T4 therapy in congenital athyreosis compared with adult-acquired hypothyroidism suggests a persisting thyroid hormone resistance at the hypothalamic-pituitary level[J]. European Journal of Endocrinology, 2014, 171(5):615~621.
[8] Furthermore. The effect of levothyroxine discontinuation timing on postoperative hypothyroidism after hemithyroidectomy for papillary thyroid microcarcinoma[J]. International Journal of Endocrinology, 2016, 20(8):1~6.
[9] Santoro A B, Vargens D D, Filho M D C B, et al. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer[J]. British Journal of Clinical Pharmacology, 2014, 78(5):1067~1075.
[10] 廖宁,肖国有,冷志欣.分化型甲状腺癌131I诊治前停用左旋甲状腺素时间的临床研究[J].中华核医学与分子影像杂志,2015,35(4):306~307.
[11] 曹晓红,陈平,陈树,等.丙硫氧嘧啶与甲状腺素片治疗老年甲亢的疗效比较[J].西南国防医药,2017,9(12):1279~1281. |
|
|
|
2018, Vol. 24 
